|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jung HI, Jeong D, Ji S, Ahn TS, Bae SH,
Chin S, Chung JC, Kim HC, Lee MS and Baek MJ: Overexpression of
PD-L1 and PD-L2 is associated with poor prognosis in patients with
Hepatocellular carcinoma. Cancer Res Treat. 49:246–254. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vilarinho S and Taddei T: Therapeutic
strategies for hepatocellular carcinoma: New advances and
challenges. Curr Treat Options Gastroenterol. 13:219–234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sangro B, Palmer D and Melero I:
Immunotherapy of hepatocellular carcinoma. Hepat Oncol. 1:433–446.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang H, Jung W, Kim A, Kim HK, Kim WB,
Kim JH and Kim BH: Expression and prognostic significance of
programmed death protein 1 and programmed death ligand-1, and
cytotoxic T lymphocyte-associated molecule-4 in hepatocellular
carcinoma. APMIS. 125:690–698. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farkona S, Diamandis EP and Blasutig IM:
Cancer immunotherapy: the beginning of the end of cancer? BMC Med.
14:732016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishimura H, Agata Y, Kawasaki A, Sato M,
Imamura S, Minato N, Yagita H, Nakano T and Honjo T:
Developmentally regulated expression of the PD-1 protein on the
surface of double-negative (CD4-CD8-) thymocytes. Int Immunol.
8:773–780. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thompson RH, Kuntz SM, Leibovich BC, Dong
H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H,
et al: Tumor B7-H1 is associated with poor prognosis in renal cell
carcinoma patients with long-term follow-up. Cancer Res.
66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and
Xu N: Immunohistochemical localization of programmed death-1
ligand-1 (PD-L1) in gastric carcinoma and its clinical
significance. Acta Histochem. 108:19–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang
JY, Yang YP, Tien P and Wang FS: PD-1 and PD-L1 upregulation
promotes CD8(+) T-cell apoptosis and postoperative recurrence in
hepatocellular carcinoma patients. Int J Cancer. 128:887–896. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maine CJ, Aziz NH, Chatterjee J, Hayford
C, Brewig N, Whilding L, George AJ and Ghaem-Maghami S: Programmed
death ligand-1 over-expression correlates with malignancy and
contributes to immune regulation in ovarian cancer. Cancer Immunol
Immunother. 63:215–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Norde WJ, Hobo W, van der Voort R and
Dolstra H: Coinhibitory molecules in hematologic malignancies:
Targets for therapeutic intervention. Blood. 120:728–736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Kang S, Shen J, He J, Jiang L,
Wang W, Guo Z, Peng G, Chen G, He J and Liang W: Prognostic
significance of programmed cell death 1 (PD-1) or PD-1 ligand 1
(PD-L1) expression in epithelial-originated cancer: A
meta-analysis. Medicine (Baltimore). 94:e5152015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X,
Yan S, Xu R and Yang D: Programmed cell death ligand 1 (PD-L1)
expression on gastric cancer and its relationship with
clinicopathologic factors. Int J Clin Exp Pathol. 8:11084–11091.
2015.PubMed/NCBI
|
|
18
|
Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ,
Jin YT and Chang Y: Increase of programmed death-1-expressing
intratumoral CD8 T cells predicts a poor prognosis for
nasopharyngeal carcinoma. Mod Pathol. 23:1393–1403. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muenst S, Hoeller S, Dirnhofer S and
Tzankov A: Increased programmed death-1+ tumor-infiltrating
lymphocytes in classical Hodgkin lymphoma substantiate reduced
overall survival. Hum Pathol. 40:1715–1722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thompson RH, Dong H, Lohse CM, Leibovich
BC, Blute ML, Cheville JC and Kwon ED: PD-1 is expressed by
tumor-infiltrating immune cells and is associated with poor outcome
for patients with renal cell carcinoma. Clin Cancer Res.
13:1757–1761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Swaika A, Hammond WA and Joseph RW:
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Mol Immunol. 67:4–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong
L and Fan Y: PD-L1 and c-MET expression and survival in patients
with small cell lung cancer. Oncotarget. 8:53978–53988.
2017.PubMed/NCBI
|
|
23
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goyal L, Muzumdar MD and Zhu AX: Targeting
the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res.
19:2310–2318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M,
Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression
of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin
Cancer Res. 15:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M,
Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ and Yang DL:
Immunostaining of PD-1/PD-Ls in liver tissues of patients with
hepatitis and hepatocellular carcinoma. World J Gastroenterol.
17:3322–3329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kleponis KJ, Skelton R and Zheng L:
Fueling the engine and releasing the break: combinational therapy
of cancer vaccines and immune checkpoint inhibitors. Cancer Biol
Med. 12:201–208. 2015.PubMed/NCBI
|
|
28
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 does
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baik CS, Rubin EH, Forde PM, Mehnert JM,
Collyar D, Butler MO, Dixon EL and Chow LQM: Immuno-oncology
clinical trial design: limitations, challenges, and opportunities.
Clin Cancer Res. 23:72017. View Article : Google Scholar
|
|
30
|
Gelsomino F, Rossi G and Tiseo M: MET and
small-cell lung cancer. Cancers (Basel). 6:2100–2115. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim R, Keam B, Kwon D, Ock Cy, Kim M, Kim
TM, Kim HJ, Jeon YK, Park IK, Kang CH, et al: Programmed death
ligand-1 expression and its prognostic role in esophageal squamous
cell carcinoma. World J Gastroenterol. 22:8389–8397. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y,
Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, et al: Upregulation of
circulating PD-L1/PD-1 is associated with poor post-cryoablation
prognosis in patients with HBV-related hepatocellular carcinoma.
PLoS One. 6:e236212011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vennapusa B, Baker B, Kowanetz M, Boone J,
Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, et
al: Development of a PD-L1 companion diagnostic
Immunohistochemistry assay (SP142) for atezolizumab. Appl
immunohistochem Mol Morphol. 27:92–100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schats KA, Van Vre EA, De Schepper S,
Boeckx C, Schrijvers DM, Waelput W, Fransen E, Vanden Bempt I,
Neyns B, De Meester I and Kockx MM: Validated programmed cell death
ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal
similar immune cell staining patterns in melanoma when using the
same sensitive detection system. Histopathology. 70:253–263. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balar AV, Galsky MD, Rosenberg JE, Powles
T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J,
Perez-Gracia JL, et al: Atezolizumab as first-line treatment in
cisplatin-ineligible patients with locally advanced and metastatic
urothelial carcinoma: A single-arm, multicentre, phase 2 trial.
Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sidaway P: Bladder cancer: Atezolizumab:
An alternative to cisplatin? Nat Rev Urol. 14:672017. View Article : Google Scholar
|
|
38
|
Mizugaki H, Yamamoto N, Murakami H,
Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T and Takahashi T: Phase
I dose-finding study of monotherapy with atezolizumab, an
engineered immunoglobulin monoclonal antibody targeting PD-L1, in
Japanese patients with advanced solid tumors. Invest New Drugs.
34:596–603. 2016. View Article : Google Scholar
|
|
39
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rebelatto MC, Midha A, Mistry A, Sabalos
C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins
JA and Walker J: Development of a programmed cell death ligand-1
immunohistochemical assay validated for analysis of non-small cell
lung cancer and head and neck squamous cell carcinoma. Diagn
Pathol. 11:952016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Diggs LP and Hsueh EC: Utility of PD-L1
immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor
response. Biomark Res. 5:122017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ilie M, Long-Mira E, Bence C, Butori C,
Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K,
et al: Comparative study of the PD-L1 status between surgically
resected specimens and matched biopsies of NSCLC patients reveal
major discordances: A potential issue for anti-PDL1 therapeutic
strategies. Ann Oncol. 27:147–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kitazono S, Fujiwara Y, Tsuta K, Utsumi H,
Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe
S, et al: Reliability of small biopsy samples compared with
resected specimens for the determination of programmed death-ligand
1 expression in non-smallcell lung cancer. Clin Lung Cancer.
16:385–390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Konishi J, Yamazaki K, Azuma M, Kinoshita
I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small
cell lung cancer cells and its relationship with tumor-infiltrating
lymphocytes and their PD-1 expression. Clin Cancer Res.
10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Azuma K, Ota K, Kawahara A, Hattori S,
Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et
al: Association of PD-L1 overexpression with activating EGFR
mutations in surgically resected nonsmall-cell lung cancer. Ann
Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang Y, Fang W, Zhang Y, Hong S, Kang S,
Yan Y, Chen N, Zhan J, He X, Qin T, et al: The association between
PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced
non-small cell lung cancer patients treated with EGFR-TKIs.
Oncotarget. 6:14209–14219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gabrielson A, Wu Y, Wang H, Jiang J,
Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L,
et al: Intratumoral CD3 and CD8 T-cell densities associated with
relapse-free survival in HCC. Cancer Immunol Res. 4:419–430. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim JH, Kim HS, Kim BJ, Jang HJ and Lee J:
Prognostic value of c-Met overexpression in hepatocellular
carcinoma: A meta-analysis and review. Oncotarget. 8:90351–90357.
2017.PubMed/NCBI
|
|
49
|
Kondo S, Ojima H, Tsuda H, Hashimoto J,
Morizane C, Ikeda M, Ueno H, Tamura K, Shimada K, Kanai Y and
Okusaka T: Clinical impact of c-MET expression and its gene
amplification in hepatocellular carcinoma. Int J Clin Oncol.
18:207–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Takeuchi H, Bilchik A, Saha S, Turner R,
Wiese D, Tanaka M, Kuo C, Wang HJ and Hoon DS: c-MET expression
level in primary colon cancer: A predictor of tumor invasion and
lymph node metastases. Clin Cancer Res. 9:1480–1488.
2003.PubMed/NCBI
|
|
51
|
Ueki T, Fujimoto J, Suzuki T, Yamamoto H
and Okamoto E: Expression of hepatocyte growth factor and its
receptor, the c-met proto-oncogene, in hepatocellular carcinoma.
Hepatology. 25:862–866. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sawada K, Radjabi AR, Shinomiya N, Kistner
E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande
Woude GF, et al: c-Met overexpression is a prognostic factor in
ovarian cancer and an effective target for inhibition of peritoneal
dissemination and invasion. Cancer Res. 67:1670–1679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shattuck DL, Miller JK, Carraway KL III
and Sweeney C: Met receptor contributes to trastuzumab resistance
of Her2overexpressing breast cancer cells. Cancer Res.
68:1471–1477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Arriola E, Cañadas I, Arumí-Uría M, Dómine
M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E,
Hirsch FR, et al: MET phosphorylation predicts poor outcome in
small cell lung carcinoma and its inhibition blocks HGF-induced
effects in MET mutant cell lines. Br J Cancer. 105:814–823. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Park S, Choi YL, Sung CO, An J, Seo J, Ahn
MJ, Ahn JS, Park K, Shin YK, Erkin OC, et al: High MET copy number
and MET overexpression: Poor outcome in non-small cell lung cancer
patients. Histol Histopathol. 27:197–207. 2012.PubMed/NCBI
|
|
56
|
Nakamura Y, Niki T, Goto A, Morikawa T,
Miyazawa K, Nakajima J and Fukayama M: c-Met activation in lung
adenocarcinoma tissues: An immunohistochemical analysis. Cancer
Sci. 98:1006–1013. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ichimura E, Maeshima A, Nakajima T and
Nakamura T: Expression of c-met/HGF receptor in human non-small
cell lung carcinomas in vitro and in vivo and its prognostic
significance. Jpn J Cancer Res. 87:1063–1069. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Takanami I, Tanaka F, Hashizume T, Kikuchi
K, Yamamoto Y, Yamamoto T and Kodaira S: Hepatocyte growth factor
and c-Met/hepatocyte growth factor receptor in pulmonary
adenocarcinomas: An evaluation of their expression as prognostic
markers. Oncology. 53:392–397. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Siegfried JM, Weissfeld LA, Singh-Kaw P,
Weyant RJ, Testa JR and Landreneau RJ: Association of
immunoreactive hepatocyte growth factor with poor survival in
resectable non-small cell lung cancer. Cancer Res. 57:433–439.
1997.PubMed/NCBI
|
|
60
|
Danilkovitch-Miagkova A and Zbar B:
Dysregulation of Met receptor tyrosine kinase activity in invasive
tumors. J Clin Invest. 109:863–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Boccaccio C and Comoglio PM: Invasive
growth: A MET-driven genetic programme for cancer and stem cells.
Nat Rev Cancer. 6:637–645. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wu F, Wu L, Zheng S, Ding W, Teng L, Wang
Z, Ma Z and Zhao W: The clinical value of hepatocyte growth factor
and its receptor-c-met for liver cancer patients with hepatectomy.
Dig Liver Dis. 38:490–497. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang ZL, Liang P, Dong BW, Yu XL and Yu
DJ: Prognostic factors and recurrence of small hepatocellular
carcinoma after hepatic resection or microwave ablation: A
retrospective study. J Gastrointest Surg. 12:327–337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kelley PK, Verslype C, Cohn AL, Yang TS,
Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, et al:
Carbozantinib in hepatocellular carcinoma: Results of a phase 2
placebo-controlled randomized discontinuation study. Ann Oncol.
28:528–534. 2017. View Article : Google Scholar : PubMed/NCBI
|
